Who are Aliskiren 150's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tekturna, Capozide 25/15, Keverprazan 14 days, Aliskiren, Perindopril, Valsartan/aliskiren, Aliskiren + Valsartan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aliskiren-150.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Aliskiren 150 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aliskiren 150 (Aliskiren 150) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct renin inhibitor. Area: Cardiovascular.

phase 3 Direct renin inhibitor Renin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aliskiren 150 (Aliskiren 150) — Novartis. Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system (RAAS) by preventing renin from converting angiotensinogen to angiotensin I.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aliskiren 150 TARGET	Aliskiren 150	Novartis	phase 3	Direct renin inhibitor	Renin
Tekturna	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Keverprazan 14 days	Keverprazan 14 days	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	direct renin inhibitor	renin
Aliskiren, Perindopril	Aliskiren, Perindopril	Medical University of Gdansk	marketed	Antihypertensive combination (direct renin inhibitor + ACE inhibitor)	Renin and Angiotensin-Converting Enzyme (ACE)
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)
Aliskiren + Valsartan	Aliskiren + Valsartan	HeartDrug Research LLC	marketed	Direct renin inhibitor + angiotensin II receptor blocker combination	Renin and AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct renin inhibitor class)

Medical Practice Prof D. Ivanov · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aliskiren 150 — Competitive Intelligence Brief. https://druglandscape.com/ci/aliskiren-150. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing